Comparative Pharmacology
Head-to-head clinical analysis: CHIRHOSTIM versus HUMATROPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIRHOSTIM versus HUMATROPE.
CHIRHOSTIM vs HUMATROPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic tripeptide (l-prolyl-l-lysyl-l-phenylalanyl) that stimulates phagocytosis via activation of mononuclear phagocytes and polymorphonuclear leukocytes through binding to formyl peptide receptors (FPRs), enhancing chemotaxis, superoxide production, and bactericidal activity. Also enhances natural killer (NK) cell activity and modulates cytokine release (e.g., IL-1, IL-6, TNF-α).
HUMATROPE (somatropin) is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating JAK2/STAT signaling pathways, leading to increased IGF-1 production and various anabolic, lipolytic, and anti-insulin effects.
Subcutaneous injection: 0.5 mg/kg once daily. Maximum dose: 40 mg/day.
0.2 mg/kg subcutaneously once daily (maximum 0.3 mg/kg per day) for growth hormone deficiency; individualize dose based on clinical response and serum IGF-1 levels.
None Documented
None Documented
Terminal elimination half-life is 14-16 hours; clinically, steady-state is achieved in approximately 3-4 days.
Terminal elimination half-life: 3.5–4.5 hours (IV) in adults; longer (6–8 hours) in children; clinical significance: supports daily subcutaneous dosing for growth hormone deficiency.
Primarily renal (70-85% as unchanged drug); biliary/fecal (10-20%) with enterohepatic recirculation.
Renal (biliary/fecal negligible).
Category C
Category C
Growth Hormone
Growth Hormone